KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to 1636.86%.

  • Arbutus Biopharma's EBIT Margin fell 356700.0% to 1636.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 320.44%, marking a year-over-year increase of 9126200.0%. This contributed to the annual value of 1236.74% for FY2024, which is 8062000.0% down from last year.
  • Arbutus Biopharma's EBIT Margin amounted to 1636.86% in Q3 2025, which was down 356700.0% from 13.86% recorded in Q2 2025.
  • Arbutus Biopharma's EBIT Margin's 5-year high stood at 13.86% during Q2 2025, with a 5-year trough of 1636.86% in Q3 2025.
  • Over the past 5 years, Arbutus Biopharma's median EBIT Margin value was 648.66% (recorded in 2021), while the average stood at 723.96%.
  • As far as peak fluctuations go, Arbutus Biopharma's EBIT Margin tumbled by -11383800bps in 2024, and later skyrocketed by 12643200bps in 2025.
  • Quarter analysis of 5 years shows Arbutus Biopharma's EBIT Margin stood at 648.66% in 2021, then skyrocketed by 44bps to 361.28% in 2022, then tumbled by -168bps to 967.23% in 2023, then increased by 8bps to 885.2% in 2024, then crashed by -85bps to 1636.86% in 2025.
  • Its last three reported values are 1636.86% in Q3 2025, 13.86% for Q2 2025, and 1456.86% during Q1 2025.